AndhraNews.net
Home » Business News » 2014 » October » October 20, 2014

Revalesio's RNS60 Demonstrates Promise in Treating Alzheimer's Disease and Other Dementias


October 20, 2014 - Tacoma, WA

Revalesio Corporation and Rush University Medical Center's Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer's disease and other forms of dementia by protecting neuronal function, restoring neuronal connections and promoting neuronal plasticity.

RNS60 is a therapeutic saline containing highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. Revalesio demonstrated the ability of RNS60 to reduce the inflammatory responses linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. The company's latest research with Rush University Medical Center investigated the potential application of RNS60 for treating Alzheimer's disease and other forms of dementia.

"The impact of RNS60 on Alzheimer's disease as outlined in our studies presents new opportunities for hope and deeper research in treating a disease that currently cannot be prevented, cured or even successfully managed," said Dr. Kalipada Pahan, Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair of Neurology at the Rush University Medical Center. "Our findings sparked tremendous excitement for RNS60, identifying an opportunity for advanced research to develop a novel treatment to help the rapidly increasing number of Alzheimer's disease and dementia patients."

"Early RNS60 results from in vitro research and animal studies, coupled with high tolerability experience for both the inhaled and injectable formulations, are very promising and encouraging for all of us at Revalesio. There are multiple projects underway that will help validate and expand our understanding of RNS60," said Bert van den Bergh, President of Revalesio Corporation and former President of Neuroscience Products at Eli Lilly & Company. "Dr. Pahan's impressive results have also motivated us to accelerate our initial human proof of concept studies so we can determine initial efficacy and safety in people with Alzheimer's disease. Our scientific team is giving this their highest priority and we look forward to working with various collaborators and partners around the globe to move RNS60 forward rapidly toward a possible use in Alzheimer's disease."

Alzheimer's disease is characterized by the presence of neuritic plaques composed of amyloid-β (Aβ) protein, neurofibrillary tangles composed of hyperphosphorylated tau protein and extensive neuronal cell death. The initial Rush University Medical Center study examined the effects of RNS60 against these factors in a transgenic animal model of Alzheimer's disease. The results establish RNS60 as a means to suppress neuronal loss, attenuate tau phosphorylation and protect memory functions in animal models with advanced Alzheimer's disease.

Rush University Medical Center then conducted a second study to determine the impact of RNS60 on neuronal plasticity, which is damaged by Alzheimer's disease. The results identified enhanced morphological plasticity in hippocampal neurons after treatment with RNS60, which could lead to restored learning and memory functions for Alzheimer's patients.

The Rush University Medical Center and Revalesio research studies are available in PLOS ONE, an international, peer-reviewed, open-access publication.

Researchers at New York University also recently published research findings in Frontiers in Neuroscience, stating that RNS60 enhances synaptic transmission via its effects on ATP production, which may have profound implications in aging and diseased brains.

Contact Revalesio to learn more about RNS60 and the opportunity for research partnerships.

About Revalesio Corporation
Revalesio is a clinical-stage biomedical company dedicated to improving health. Based in Tacoma, Washington, Revalesio partners with leaders in biomedical research around the world to develop RNS60 to address a variety of therapeutic needs. The privately held company was founded by the Russell Family in 2006 and has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of charge-stabilized nanostructures (CSNs) in treating neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

FOR MORE INFORMATION:
Gabe Boeckman
Voxus PR
(253) 444-5377
Email Contact

MarketWire

Comment on this story

Share